Compare BLZE & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | DERM |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.8M | 194.9M |
| IPO Year | 2021 | 2021 |
| Metric | BLZE | DERM |
|---|---|---|
| Price | $15.66 | $7.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.60 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 4.5M | 338.9K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.56 | 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,835,000.00 | $61,858,000.00 |
| Revenue This Year | $10.16 | $39.72 |
| Revenue Next Year | $10.91 | $63.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.27 | 10.20 |
| 52 Week Low | $3.26 | $4.31 |
| 52 Week High | $16.59 | $9.56 |
| Indicator | BLZE | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 82.62 | 63.54 |
| Support Level | $3.93 | $7.00 |
| Resistance Level | N/A | $7.69 |
| Average True Range (ATR) | 1.21 | 0.44 |
| MACD | 0.68 | 0.06 |
| Stochastic Oscillator | 90.08 | 86.21 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.